Company Overview
Snapshot
Founded in January 2019 by Noam Solomon, Luis Voloch, and Ansuman Satpathy, Immunai operates with 51–200 employees. The company has raised $295M across 3 funding rounds from 14 investors. In October 2021, Immunai announced a $215M Series B round, highlighting the maturation of its immune cell atlas.
Business overview
Immunai is a Health Tech & Life Sciences company focused on developing a proprietary dataset of multi-omic, immune-centric peripheral tissue analyses. The company's core technology leverages advanced analytics and a data-visualization interface, powered by artificial intelligence, machine learning, and deep learning, to enable researchers to comprehensively view and interrogate data. This platform helps derive novel conclusions on the underlying mechanisms of disease and is currently applied to develop and refine cell therapies, such as for neuroblastoma in collaboration with the Baylor College of Medicine. Immunai serves the healthcare and life sciences industries, including laboratories, providers, and pharmaceutical companies, operating within the Digital Healthcare and Pharma & Medical Biotechnology sectors.
Strategic signal
In May 2026, Immunai's immune-system modeling platform extended its support for oncology drug development through 2027. This continued engagement signals strong validation of Immunai's AI-driven approach in critical therapeutic areas, demonstrating its long-term strategic value to pharmaceutical partners and its sustained impact on advancing oncology research and development.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent partnership for Immunai?
- In May 2026, Immunai announced that its immune-system modeling platform would continue supporting oncology drug development through 2027. This extends its collaboration in a critical therapeutic area.
- What was the latest funding round for Immunai?
- In October 2021, Immunai announced a $215M Series B funding round. This round highlighted the maturation of its immune cell atlas.
- Which company did Immunai acquire in August 2021?
- In August 2021, Immunai acquired Nebion. This acquisition was part of Immunai's strategy to expand its capabilities.
- What was the focus of Immunai's collaboration announced in November 2024?
- In November 2024, Immunai and Teva launched a multi-year AI collaboration aimed at enhancing precision in immunology and oncology trials by utilizing Immunai’s immune system mapping tools.
- What was the strategic focus of Immunai's acquisition in March 2021?
- In March 2021, Immunai acquired Dropprint Genomics. This acquisition was made to expand Immunai's target discovery capabilities and strengthen its leadership team with immunology experts.